Update Shareholders

 
News Articles for Update Shareholders top ^
2014/1/22
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1083822&ProfileId=051205&sourceType=1 RENO, NV --
Sign-up for PPJ Enterprise (PPJE: PK) Updates Shareholders on Collection Lawsuit investment picks
2014/3/24
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1100415&ProfileId=051205&sourceType=1 RENO, NV --
Sign-up for PPJ Enterprise Updates Shareholders investment picks
2014/1/23
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1084297&ProfileId=051205&sourceType=1 RENO, NV --
Sign-up for PPJ Enterprise (PPJE: PK) Updates Shareholders on New Developments in Its Collection Lawsuit investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1075889&ProfileId=051205&sourceType=1 CARSON CITY, NV --
Sign-up for Rapid Fire Marketing Updates Shareholders on Multiple Topics investment picks
HOUSTON, Aug.
Sign-up for ERHC Energy Inc. Updates Shareholders on Progress investment picks
2014/3/13
Astika Holdings, Inc. (the "Company") (OTCQB:ASKH) a strategic acquisition company of service, agriculture and industrial companies from the Nantong Region in China would like to update its shareholders on the progression of the previously announced Nantong Dredging acquisition.
Sign-up for Astika Holdings, Inc. Updates Shareholders on the Nantong Dredging Acquisition investment picks
2013/8/14
BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI), leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, August 20, 2013 at 8:45 a.m. Eastern Daylight Time, 15:45 Israel Daylight Time.
Sign-up for BrainStorm Cell Therapeutics Will Host a Conference Call to Update Shareholders on Recent Company Developments investment picks
2013/11/12
BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, November 19, 2013 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST). Mr.
Sign-up for BrainStorm Cell Therapeutics Will Host a Conference Call to Update Shareholders on Recent Positive Company Developments investment picks
2014/1/15
BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Thursday, January 30, 2014 at 8:45 a.m. Eastern Standard Time (EST), 15:45 Israel Standard Time (IST). Mr.
Sign-up for BrainStorm Hosting a Conference Call with Clinical Trial Advisors in Israel, US and Brazil to Update Shareholders on Current Developments investment picks
2014/1/21
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1082830&ProfileId=051205&sourceType=1 LAS VEGAS, NV --
Sign-up for Texas Wyoming Drilling, Inc. (OTCPink: TWDL), a US-Based Exploration Mining Company Updates Shareholders Concerning Geographical Surveys on Its Yellow Jacket Placer Mining Claim investment picks
2014/3/10
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1096644&ProfileId=051205&sourceType=1 RENO, NV --
Sign-up for PPJ Enterprise Updates Shareholders investment picks
2014/1/23
By Christina Rexrode, MarketWatch NEW YORK (MarketWatch) -- At a public company, a board of directors is supposed to stand up for the rights of shareholders.
Sign-up for UPDATE: Shareholders push for more say over board members investment picks
Vertex Energy, Inc. (NASDAQ: VTNR ), an environmental services company that recycles industrial waste streams and off-specification commercial chemical products, provides shareholders with an update on its corporate accomplishments, its progress and business development efforts, and highlights its business plan for 2013 and beyond.
Sign-up for Vertex Energy Inc. Updates Shareholders in Its CEO Letter investment picks
2013/10/7
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1057091&ProfileId=051205&sourceType=1 TULSA, OK --
Sign-up for Efftec International, Inc. Announces Asset Sale and Updates Shareholders on Current Activities investment picks
Incyte Corporation (Nasdaq: INCY) today reported second-quarter 2013 financial results, including revenue from Jakafi ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also increased its 2013 net product revenue guidance to a range of $220 million to $230 million, a change from the previous range of $210 million to $225 million; highlighted additional positive data recently presented at key scientific meetings for its lead JAK1 and JAK2 inhibitors, Jakafi and baricitinib, and its novel immunotherapy, INCB24360, an oral IDO1 inhibitor; and described progress for several other clinical programs, including additional potential indications for Jakafi.
Sign-up for Incyte Reports Second-Quarter 2013 Financial Results; Increases Revenue Guidance; Updates Shareholders on Key Clinical Programs investment picks
2013/7/15
EAST RUTHERFORD, N.J., July 15, 2013 (GLOBE NEWSWIRE) -- MamaMancini's Holdings, Inc. (the "Company") (OTCBB:MMMB) , a marketer of specialty pre-prepared and frozen and refrigerated foods, is issuing this statement to bring investors up to date on current operating results.
Sign-up for MamaMancini's Holdings, Inc. Updates Shareholders Regarding Operating Results investment picks
2013/10/31
Incyte Corporation (Nasdaq: INCY) today reported third-quarter 2013 financial results, including revenue from Jakafi ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also described: positive top-line results of its Phase II trial (RECAP) of ruxolitinib in patients with refractory metastatic pancreatic cancer; positive Phase II proof-of-concept data recently presented at key scientific meetings for its lead JAK1 inhibitor, INCB39110; and progress for several of its other key clinical programs.
Sign-up for Incyte Reports Third-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs investment picks
2014/2/12
Incyte Corporation (Nasdaq: INCY) today reported 2013 fourth-quarter and year-end financial results, including revenue from Jakafi ® (ruxolitinib), which is approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF). The Company also provided 2014 financial guidance and highlighted multiple achievements in its clinical programs, including agreement with the FDA for a Special Protocol Assessment (SPA) for a registration trial of ruxolitinib in patients with advanced or metastatic pancreatic cancer.
Sign-up for Incyte Reports 2013 Fourth-Quarter and Year-End Financial Results; Provides 2014 Financial Guidance; Updates Shareholders on Key Clinical Programs investment picks
2014/2/27
Exceeded 2013 Production Guidance with Lower than Projected Capital Expenditures - Produced 33.8 MMBoe, 1% more than guidance of 33.6 MMBoe - Spent $1.424 Billion, 2% less than guidance of $1.450 Billion Increased Mid-Continent Production 8% to 51.7 MBoe per Day from the Previous Quarter, 44% Above the Fourth Quarter of 2012 Delivered 80 Mid-Continent Wells with an Average 30-day IP of 386 Boe per Day during the Fourth Quarter; 2013 Average 30-day IP was 366 Boe per Day Successful Appraisal Program Adds Sumner County, Kansas to the Focus Area Increased PUD Type Curve: Oil EUR Up 10% and Boe EUR Up 3% 434% Reserve Replacement and All-in Finding and Development Cost of $11.72 per Boe, Based on Retained Properties OKLAHOMA CITY , Feb.
Sign-up for SandRidge Energy, Inc. Updates Shareholders on Operations and Reports Financial Results for Fourth Quarter and Full Year 2013 investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Update Shareholders
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Update Consumers  |  Next: Updated Corporate Presentation